Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the filing requirements for the use of ibrutinib in patients with mantle cell lymphoma (MCL) and in patients with Waldenstrom's macroglobulinemia (WM). The Company expects to finalize the MCL filing prior to year end and will provide guidance on the WM filing after further discussions with the FDA. Pharmacyclics will provide regulatory updates as further information on implementing the requirements with respect to Breakthrough Therapies are developed by the Secretary of Health and Human Services.

ASH 2012

Pharmacyclics had 9 oral and 9 poster presentations at this year's American Society of Hematology (ASH) Annual Meeting providing an update on the broad development program of ibrutinib.  Among the data presented at ASH were updates on the safety and efficacy of ibrutinib in the most mature clinical programs of chronic lymphocytic leukemia (CLL) and MCL. Two of the CLL oral presentations were acknowledged as 'Best of ASH' during the event. Additionally, investigators presented data in diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM).  Most of the oral presentations can be found on the Company's website. 

Phase II/III clinical trials initiated with ibrutinib in the collaboration:

  • Phase III study of ibrutinib versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), RESONATE™. This trial is a randomized, multi-center, open-label Phase III trial of ibrutinib as a monotherapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to ofatumumab. This global study is open and Pharmacyclics plans to enroll 350 patients worldwide. The Company anticipates having this st
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... PROVO, Utah , July 10, 2014 ... genome annotation and interpretation, today announced an ... sequencing (NGS) analytics for Lineagen,s NextStep Dx ... evaluation of neurodevelopmental and neurological disorders, currently ... chromosomal microarray (CMA) testing service used by ...
    (Date:7/10/2014)... --  Ceres, Inc . (Nasdaq: CERE ), ... results for the three months ended May 31, 2014 ... Ceres reported that the company and its customers have ... in Brazil, which concluded in June, despite dry and ... for part of the growing season. Yields of several ...
    (Date:7/10/2014)... research may help in the fight against terrorism with ... quantities of explosives with the use of light and ... Sensors and Actuators B: Chemical , the researchers describe ... in concentrations as low as 6.3 ppm (parts per ... few minutes. , "Traditionally explosives detection has involved looking ...
    (Date:7/10/2014)... journal PNAS (Proceedings of the National Academy of ... sleep deprivation have a significant effect on our metabolism. ... best time of day to test for diseases such ... effectively. , Researchers from the University of Surrey and ... between sleep deprivation, body clock disruption and metabolism, and ...
    Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2Time of day crucial to accurately test for diseases, new research finds 2
    ... , SEATTLE, Sept. 10 Cell Therapeutics, Inc. ... the Biotech Industry conference on Wednesday, September 16, 2009, at 10:30 AM ... 16, 2009, at the Millennium Broadway Hotel in New York. The ... the presentation. The webcast can be accessed at www.celltherapeutics.com ...
    ... , CARLISLE, Pa., Sept. 9 Hanson ... pathogen screening, today announced the issuance of a U.S. Patent ... Microorganisms. The U.S. patent describes the Company,s method for screening ... and other plant material intended for human and animal consumption. ...
    ... , CAMBRIDGE, Mass., Sept. 9 ... development of next-generation cellulosic ethanol and high-performance specialty enzymes, announced that ... at 5:00 p.m. today. Verenium,s shares will continue to trade ... letter "D" added to the end of the trading symbol for ...
    Cached Biology Technology:Hanson Technologies, Inc. Awarded Patent for its Advanced Food Pathogen Detection System 2Verenium 1:12 Reverse Stock Split Takes Effect 2Verenium 1:12 Reverse Stock Split Takes Effect 3Verenium 1:12 Reverse Stock Split Takes Effect 4
    (Date:7/11/2014)... University of Chicago is creating a new professorship ... the University,s Institute for Molecular Engineering and the ... donation from the Millicent and Eugene Bell Foundation., ... reside within the Institute for Molecular Engineering. That ... project at the MBL,s Eugene Bell Center for ...
    (Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
    (Date:7/11/2014)... 11, 2014 The increased risk of kidney injury ... resuscitation fluids reflects the mass of HES molecules, according ... official journal of the International Anesthesia Research Society (IARS). ... harmful effect of HES on cultured human renal proximal ... Christian Wunder and colleagues of University Hospital Wrzburg, Austria. ...
    Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2A new genome editing method brings the possibility of gene therapies closer to reality 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
    ... from blood poisoning? To answer this question, the doctor draws ... for testing. This takes up valuable time, which could cost ... to analyze blood there and then and have the results ... developed by scientists at the Fraunhofer Institute for Physical Measurement ...
    ... considering scores of applications to develop utility-scale solar power ... but too little is known to judge their likely ... the December 2011 issue of BioScience . Although ... technology, available information suggests a worrisome range of possible ...
    ... ARLINGTON, Va.Underscoring the importance of alternative energy for the ... Corps Base Hawaii Dec. 7 to learn about possible ... Research (ONR)-funded fuel cell vehicles (FCV) and high-efficiency trash ... the 70th anniversary of the Pearl Harbor attack, was ...
    Cached Biology News:Recognizing blood poisoning quickly 2Solar power development in US Southwest could threaten wildlife 2New energy sources fuel interest from Secretary of the Navy 2
    ... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
    ... to create the ideal environment for nucleic acid ... , Variable speed control (10 to 15 ... be for washing or hybridizing , A ... the chamber, ,is situated above a touch sensitive ...
    ... engineered for efficient drying down of synthetic ... cover and a post-trap with ammonia neutralizing ... of samples in ammonium hydroxide., , ... , Comes standard with ...
    ... MB (for aqueous, other low volatility and ... respond to specific applications of molecular biology ... of heat-labile samples. The RC systems can ... traps and a wide selection of rotors ...
    Biology Products: